Foghorn Therapeutics Inc.

For the period ended Dec 31, 2025. Filed Mar 11, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 11, 2026

FHTX$1.90-6.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Deficit

(In thousands, except share amounts)

Common Stock · AdditionalPaid-inCapital · AccumulatedOtherComprehensiveGain (Loss) · AccumulatedDeficit · TotalStockholders’Deficit
Shares · Amount
Balances at December 31, 2023	42,282,040	$4	$395,196	$(826)	$(471,564)	$(77,190)
Issuance of common stock and pre-funded warrants, net of underwriting discounts, commissions, and offering costs	12,743,039	2	102,814	—	—	102,816
Issuance of common stock upon exercise of stock options and employee stock purchase plan	569,052	—	2,612	—	—	2,612
Stock-based compensation expense	—	—	11,893	—	—	11,893
Unrealized gains on marketable securities	—	—	—	961	—	961
Net loss	—	—	—	—	(86,620)	(86,620)
Balances at December 31, 2024	55,594,131	6	512,515	135	(558,184)	(45,528)
Issuance of common stock upon exercise of stock options and employee stock purchase plan	236,075	—	483	—	—	483
Issuance of common stock upon exercise of pre-funded warrants	725,949	—	—	—	—	—
Issuance of common stock under the ATM Facility, net of issuance costs	101,174	—	540	—	—	540
Stock-based compensation expense	—	—	10,399	—	—	10,399
Unrealized losses on marketable securities	—	—	—	(111)	—	(111)
Net loss	—	—	—	—	(74,283)	(74,283)
Balances at December 31, 2025	56,657,329	$6	$523,937	$24	$(632,467)	$(108,500)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.